Literature DB >> 19089362

Isolation, propagation, and characterization of human umbilical cord perivascular cells (HUCPVCs).

Rahul Sarugaser1, Jane Ennis, William L Stanford, John E Davies.   

Abstract

Current sources of mesenchymal cells, including bone marrow, fat and muscle, all require invasive procurement procedures, and provide relatively low frequencies of progenitors. Here, we describe the non-invasive isolation, and characterization, of a rich source of mesenchymal progenitor cells, which we call human umbilical cord perivascular cells (HUCPVCs). HUCPVCs show a similar immunological phenotype to bone marrow-derived mesenchymal stromal cells (BM-MSCs), since they are non-alloreactive, exhibit immunosuppression, and significantly reduce lymphocyte activation, in vitro. They present a non-hematopoietic myofibroblastic mesenchymal phenotype (CD45-, CD34-, CD105+, CD73+, CD90+, CD44+, CD106+, 3G5+, CD146+); with a 1:300 frequency at harvest, a short-doubling time, and a clonogenic frequency of >1:3 in culture. Furthermore, in addition to robust quinti-potential differentiation capacity in vitro, HUCPVCs have been shown to contribute to both musculo-skeletal and dermal wound healing in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19089362     DOI: 10.1007/978-1-59745-060-7_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  33 in total

1.  [Mesenchymal stem cells for bone tissue engineering].

Authors:  R K Schneider; S Neuss; R Knüchel; A Perez-Bouza
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord.

Authors:  Ingrida Majore; Pierre Moretti; Frank Stahl; Ralf Hass; Cornelia Kasper
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 3.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

4.  A safe and efficient method to retrieve mesenchymal stem cells from three-dimensional fibrin gels.

Authors:  Bita Carrion; Isaac A Janson; Yen P Kong; Andrew J Putnam
Journal:  Tissue Eng Part C Methods       Date:  2013-08-14       Impact factor: 3.056

5.  Combining adult stem cells and olfactory ensheathing cells: the secretome effect.

Authors:  Nuno A Silva; Jeffrey M Gimble; Nuno Sousa; Rui L Reis; António J Salgado
Journal:  Stem Cells Dev       Date:  2013-01-14       Impact factor: 3.272

6.  In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells.

Authors:  Peter Szaraz; Yarden S Gratch; Farwah Iqbal; Clifford L Librach
Journal:  J Vis Exp       Date:  2017-08-09       Impact factor: 1.355

7.  Comparison of equine bone marrow-, umbilical cord matrix and amniotic fluid-derived progenitor cells.

Authors:  Arianna Barbara Lovati; Bruna Corradetti; Anna Lange Consiglio; Camilla Recordati; Elisa Bonacina; Davide Bizzaro; Fausto Cremonesi
Journal:  Vet Res Commun       Date:  2010-12-31       Impact factor: 2.459

8.  Form Follows Function: Advances in Trilayered Structure Replication for Aortic Heart Valve Tissue Engineering.

Authors:  Dan T Simionescu; Joseph Chen; Michael Jaeggli; Bo Wang; Jun Liao
Journal:  J Healthc Eng       Date:  2012-06       Impact factor: 2.682

9.  Influence of obstetric factors on osteogenic potential of umbilical cord-derived mesenchymal stem cells.

Authors:  Letizia Penolazzi; Renata Vecchiatini; Stefania Bignardi; Elisabetta Lambertini; Elena Torreggiani; Alessandro Canella; Tiziana Franceschetti; Giorgio Calura; Fortunato Vesce; Roberta Piva
Journal:  Reprod Biol Endocrinol       Date:  2009-10-05       Impact factor: 5.211

10.  Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy.

Authors:  Rahul Sarugaser; Lorraine Hanoun; Armand Keating; William L Stanford; John E Davies
Journal:  PLoS One       Date:  2009-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.